.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Decitabine is a critical DNA hypomethylating agent used for treating myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Traditionally, its poor oral decitabine bioavailability required patients to undergo frequent intravenous infusions. However, the development of a fixed-dose combination with cedazuridine has revolutionized treatment options. This oral medication achieves systemic exposure equivalent to intravenous therapy by preventing the rapid degradation of decitabine in the digestive system and liver.
While clinicians primarily attribute the boost in oral decitabine bioavailability to the inhibition of cytidine deaminase (CDA), recent research suggests a more complex interaction. Cedazuridine effectively blocks first-pass metabolism in the gut and liver, where CDA usually degrades decitabine. Furthermore, new evidence shows that cedazuridine influences renal elimination. By interacting with the concentrative nucleoside transporter 1 (CNT1) in the kidneys, cedazuridine reduces the renal clearance of decitabine. Consequently, this dual mechanism ensures more consistent and higher drug levels in the bloodstream, mimicking the effects of a continuous infusion.
Understanding these pharmacokinetic drivers is essential for optimizing patient outcomes in hematological care. The interplay between CDA inhibition and renal transporter modulation highlights why this combination is so effective. Additionally, it provides a scientific framework for predicting potential drug-drug interactions involving renal transport pathways. As more oral therapies enter the oncology space, these insights will help clinicians manage treatment protocols more precisely for patients in India and worldwide.
Decitabine has very poor oral decitabine bioavailability on its own because the enzyme cytidine deaminase (CDA) quickly breaks it down in the digestive tract and liver before it reaches the bloodstream.
Cedazuridine acts as a potent CDA inhibitor, protecting decitabine from early degradation. It also affects renal transporters like CNT1, which helps maintain therapeutic levels of the drug by reducing its loss through urine.
Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. It is not a substitute for professional clinical judgment or direct patient care. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A recent study identifies CDA inhibition and CNT1-mediated tubular reabsorption as key drivers of oral decitabine's improved bioavailability with cedazuridi...
4 months ago
Andhra Pradesh reported 10 new Covid-19 cases, taking the state tally to 49 while deaths remain at four. With 24 patients hospitalized and 16 under home isolation, the Health Department has intensified monitoring. Medical professionals should review regional distribution, diagnostic protocols, and management plans.
Today
An 11-year Swedish registry study of 618 uterine sarcoma patients found that minimally invasive surgery yielded survival comparable to open surgery in early stages. However, adjuvant chemotherapy conferred no survival benefit in localized or advanced disease, highlighting stage and histology as key outcomes.
3 days back
A cross-sectional study evaluates post-intensive care syndrome in cardiac patients 2-4 weeks post-ICU discharge, highlighting cognitive, psychological, and functional impairments and the need for structured multidisciplinary rehabilitation.
3 days back
Anterior cruciate ligament reconstruction failure lacks uniform definition. A narrative review proposes an integrative framework incorporating objective and subjective instability, persistent pain, restricted motion, graft rupture, and secondary meniscal injury to standardize clinical reporting.
3 days back
With World Obesity Atlas data warning that over 41 million Indian children are overweight or obese, ICMR and NIN have unveiled a 10-point policy roadmap. The initiative calls for mandatory front-of-pack labeling, HFSS taxes, strict marketing bans, and healthier school environments to curb non-communicable diseases.
Today
